Nomir Medical To Present Positive Onychomycosis Data For Its Noveon(R) Dual Wavelength Device

Main Category: Dermatology
Also Included In: Clinical Trials / Drug Trials
Article Date: 18 Aug 2008 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Nomir Medical Technologies, a leader in the development of optical energy technologies for anti-infective medical applications, announced that the Company will present an abstract detailing positive in vitro and in vivo human data from its study of onychomycosis (toe nail fungus) using Noveon®, a novel dual wavelength optical energy device. Noveon is designed to effect near-infrared photo-inactivation of fungi and bacteria at energies and temperatures that are safe to normal and healthy tissue.

The detailed data will be presented in a digital session at the New Cardiovascular Horizons "Wound Management of the Diabetic Foot and Wound Healing" conference in New Orleans, September 10-13, 2008.

In May 2008, Nomir initiated a pivotal product registration trial for Noveon for the onychomycosis indication.

About Nomir

Nomir Medical Technologies, Inc. is a medical device company with a product pipeline of optical energy therapeutics being developed for multiple clinical applications. Nomir's light-based systems target the elimination of bacterial and fungal infections, while also promoting healthy tissue recovery. This potential therapy-altering technology may enhance the effectiveness of, or even reduce the need for antibiotics and antifungal agents, and may be associated with fewer treatment side-effects. Nomir has a broad patent portfolio with pending systems, methods and unique photobiological mechanism claims for near infrared photodamage to bacterial and fungal pathogens. http://www.nomirmedical.com

Forward-looking statements

Certain statements contained in this press release containing words like believe, intend, may, expect, project and other similar expressions are forward-looking statements involving a number of risks and uncertainties. Factors that can cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies, therapies, and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapidly changing technologies; government regulations of our technologies; our ability to assert and enforce our intellectual property rights and protect our proprietary technologies; the ability to attract and retain key employees; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key milestones in key products and other risks factors from time to time in the Company's announcements.

Nomir Medical Technologies, Inc.